Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News NKGen Biotech Inc (EM) NKGN

Healthcare Biotechnology
NKGen Biotech, Inc., a clinical-stage biotechnology company, develops and commercializes cell therapies for neurodegenerative and oncological diseases based on activated natural killer (NK) cells in the United States. The company develops SNK01, an autologous NK cell therapy candidate in Phase I/IIa trial for the treatment of neurodegenerative diseases, such as Alzheimer’s and Parkinson's... see more

Current News (EXPM:NKGN)

NKGen Biotech, Inc. Issues Statement on Recent Board Appointments at Majority-Owned Korean Affiliate NKGen Korea Co., Ltd.

GlobeNewswire 8 days ago

NKGen Biotech Provides Clarification on Quotation Display and Trading Status on the OTC Expert Market

GlobeNewswire October 9, 2025

NKGen Biotech to Present on the Use of Troculeucel for Neurodegenerative Diseases at the XXVII World Congress of Neurology

GlobeNewswire October 6, 2025

NKGen Biotech to Present on the Use of Troculeucel for Neurodegenerative Diseases at the 3rd China Great Bay Cell and Gene Therapy Forum

GlobeNewswire September 18, 2025

NKGen Biotech, Inc. Announces Completion of NKMax Co., Ltd. Acquisition; Gains Full Control of Global Manufacturing and Intellectual Property Assets

GlobeNewswire September 9, 2025

NKGen Biotech To Present on Allogeneic Enhanced NK Cells without Lymphodepletion in Solid Tumors at the 13th Annual Immuno-Oncology Summit

GlobeNewswire August 6, 2025

NKGen Biotech Presents Troculeucel Mechanism of Action with Corresponding Phase 1 Biomarker Data at the Alzheimer's Association International Conference 2025

GlobeNewswire July 28, 2025

NKGen Biotech to Present at the Alzheimer's Association International Conference 2025

GlobeNewswire July 22, 2025

NKGen Receives FDA Expanded Access Protocol Authorization for Landmark Treatment of Several Neurodegenerative Diseases

GlobeNewswire July 21, 2025
View More News ››

Opinion & Analysis (EXPM:NKGN)

No current opinion is available.
View More Opinion ››

Bullboard Posts (EXPM:NKGN)

NKGN....N.L.O.D $1.02

Go figure....skating ! Waiting for the P.O announcement
Iseneschal - July 18, 2024

RE:NKGN....early a.m runner on NR....Caveat Emptor imho ; )

Can't say I didn't warn you.....now at $1.06 n.l.o.d All the Chasers are roasted again !!!!
Iseneschal - July 18, 2024

NKGN....early a.m runner on NR....Caveat Emptor imho ; )

Be a chaser and your going to get your face ripped off....P.O set up!!! https://www.sec.gov/Archives/edgar/data/1845459...
Iseneschal - July 18, 2024

Excellent ceo interview from NKGen!

https://youtu.be/g1qwPyAV8mM?si=Ip-B1KxPEzgncEWX
BryceCanada - November 7, 2023
View more Bullboard ››

PlasCred Circular Innovations Inc.

PlasCred Circular Innovations Inc.

PlasCred is building industrial-scale recycling infrastructure to convert mixed plastic waste into high-value hydrocarbon ...
View More »